NCT Number: NCT00247650
Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy
This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer
Looking for future studies?
Notify MeKey information
Conditions
Age range
65 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 2
Primary location
Novartis Investigative Site, Edmonton, Alberta, Canada
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Postmenopausal women
- Newly diagnosed with non metastatic breast cancer
- Candidate for mastectomy or breast-conserving surgery
Exclusion criteria
- Patients with invasive tumors
- Patients receiving anti-cancer treatment
- Patients who have undergone surgery
Other protocol-defined exclusion criteria may apply.
Treatment and study plan
Primary outcomes
-
Clinical response at 24 weeks
Secondary outcomes
-
Clinical response at 16 weeks
-
Clinical benefit at 16 weeks
-
Clinical benefit at 24 weeks
-
Rate of breast conserving surgery in both arms
-
Rate of complete pathological response
-
Biomarkers
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Novartis
Industry
Registry information
Official study title
Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)
Important dates
- Study start
- 2005
- Primary completion
- 2007
- First posted
- Nov 2, 2005
- Registry last updated
- Mar 1, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
HIIT Following Breast Cancer Chemotherapy
NCT05913713
Breast Cancer, Breast Diseases
Gainesville, Florida, United States
View Trial DetailsCDK and Body Composition Study
NCT03697577
Breast Cancer, Breast Diseases
The Bronx, New York, United States
View Trial DetailsNeoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer
NCT05444998
Breast Cancer, Breast Diseases
Xi'an, Shannxi, China
View Trial DetailsHER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT03387553
Breast Cancer, Breast Cancer Female
Tampa, Florida, United States
View Trial Details